Sernova Biotherapeutics Inc SVA

Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement PlatformTORONTO and GERMANTOWN, Md., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a clinical-stage regenerative medicine company focused on developing cell therapies with the goal of delivering a functional cure for type 1 diabetes (T1D), today announced Sernova and Serax

Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection with Seraxis's proposal ("Proposed Transaction") to acquire all of the securities of Sernova Biotherapeutics Inc. ("Sernova") pursuant to an arrangement agreement dated September 7, 2026 between Seraxis and Sernova ("Arrangement Agreement"). Pursuant to the Arrangement Agreement, holders of.

Jonathan Rigby, CEO of Sernova and Will Rust, Ph.D., CEO of Seraxis to Present Merger Details to Form BetaNova Biotherapeutics, a Differentiated Leader in Type1 Diabetes Cell TherapyTORONTO and GERMANTOWN, Md., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced it will be participatin

Merger unites Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells and in-house cGMP manufacturingThe combined entity will operate under the name BetaNova Biotherapeutics, Inc.SR-02 allogeneic islet cell therapy Phase 1/2 clinical trial in T1D expected to dose patients Q1 2027 under an FDA-cleared IND (NCT07581197) with data anticipated by mid-yearSR-03 next-generation gene-edited islet cell therapy targeting immune evasion; IND submission expected H2 2027

Cell Encapsulation Market Cell Encapsulation Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Cell Encapsulation Market by Type of Encapsulation Material, Type of Encapsulation Method, Type of Manufacturing Technique, Type of Technology, Application Area, End User, and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global cell encapsulation market is projected to increase from USD 5.7 billion in 2026 to USD 15.8 billion by 2035

(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.

TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy. S

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that it has completed the final closing of a series of previously disclosed financing transactions, following receipt of shareholder approval at the Company's

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the voting results from its Annual General Meeting of Shareholders (the "Meeting") held on April 8, 2026.At the Meeting, a total of 93,246,234 common shares were voted,

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the closing of its non-brokered private placement financing that has secured total gross proceeds of $2.1 million. The Company issued 13,762,659 units in connection...

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced financing transactions totaling $7.1 million, significantly strengthening the Company's balance sheet and financial position.The transactions include:$1.6 million equity...

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that, subject to approval from the TSX, the Company intends to amend some of its outstanding warrants.The Company issued 20,852,100 warrants pursuant to a private placement unit...

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 13, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH) ("Sernova or the Company)") a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the closing of the first tranche of a private placement totaling CAD $874,600 in gross proceeds from existing and new investors. The Company aims to raise up to $5M CAD...